COMMUNIQUÉS West-GlobeNewswire

Summit Discovers Multiple New Mechanism Antibiotics Against Novel ESKAPE Pathogen Targets
06/09/2018
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit Discovers Multiple New Mechanism Antibiotics Against Novel ESKAPE Pathogen Targets Discovery Enabled by Discuva Platform and Proprietary Bacterial Libraries [...]
BeyondSpring’s Lead Asset, Plinabulin, Shows Superior Efficacy Compared to Neulasta for Prevention of Thrombocytopenia Induced by Docetaxel in Phase 2 Trial
06/09/2018
Data Provide Further Support for Plinabulin’s Superior Product Profile Clinical Data Will be Presented at 2018 IASLC 19th World Conference on Lung Cancer NEW YORK , Sept. 06, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc [...]
Auxly and Delta 9 Announce Strategic Investment and Supply Agreement
06/09/2018
VANCOUVER, British Columbia, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Auxly Cannabis Group Inc. (TSX.V - XLY) (OTCQX:CBWTF) (" Auxly ") and Delta 9 Cannabis Inc. (TSX.V -NINE) (“ Delta 9 ”) are pleased to announce that the [...]
CDC Awards BioCryst $35 Million RAPIVAB® Contract for Strategic National Stockpile
06/09/2018
RESEARCH TRIANGLE PARK, N.C., Sept. 06, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, [...]
Emerald Health Therapeutics Announces Amendment from Health Canada for Pure Sunfarms’ Cultivation License, Expanding Cannabis Production Area to Approximately 550,000 Square Feet in One of the Single Largest Cannabis Growing Facilities in the World
06/09/2018
Entire first half of 1.1 million square foot Delta 3 greenhouse now approved for cultivation and sale VICTORIA, British Columbia, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (TSXV:EMH; OTCQX: [...]
Oncolytics Biotech® Announces a Master Clinical Supply Agreement of an Anti-PD-L1 Checkpoint Inhibitor for use in the Company’s Clinical Program
06/09/2018
CALGARY, Alberta and SAN DIEGO, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing REOLYSIN ® (pelareorep), an intravenously delivered immuno-oncolytic virus [...]
TRU NIAGEN® to be Highlighted at Vitafoods Asia 2018 in Singapore
06/09/2018
Amy Boileau, PhD, RD, to speak on the revolutionary science behind TRU NIAGEN to Asia-Pacific nutraceutical industry IRVINE, Calif., Sept. 06, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, [...]
Xenon Expands Ion Channel Neurology Pipeline with Addition of XEN496, a “Phase 3 Ready” Potassium Channel Modulator for the Treatment of Epilepsy
06/09/2018
Single, Pivotal Phase 3 Clinical Trial in Approximately 20 KCNQ2-EE Patients Expected to be Initiated in Mid-2019 Conference Call Today at 8:00 am ET Xenon to Webcast Update on Epilepsy Pipeline from Biocentury [...]
Shire Acquires sanaplasma AG Boosting Plasma Collection Network for Immunology Franchise
06/09/2018
Shire Acquires sanaplasma AG Boosting Plasma Collection Network for Immunology Franchise The acquisition of sanaplasma AG will extend long-term plasma supply in support of Shire’s growing Immunology business sanaplasma [...]
Dividend payment of “Grindeks”
06/09/2018
The joint stock company “Grindeks” shareholders’ annual general meeting held on June 26, 2018 decides on distribution of the profit for the year 2017 to set September 11, 2018 as the date of calculation of dividends. [...]
Correction: CV of Inga Krūkle, newly elected Board member of JSC Olainfarm
06/09/2018
Correction: The announcement was supplemented with information on the number of shares, owned by the member of the Board of JSC "Olainfarm" I.Krūkle and reference to the Council decision on changes in the Board of JSC [...]
Aino Health AB (publ): Aino Health provided If with solutions to the challenges of corporate health management
06/09/2018
Aino Health provided If with consulting services to solve the challenges of work ability and health management. A current status analysis, Business Health Index was carried out and root causes for sickness absences in [...]
Solon Eiendom ASA – Primary insider notification
06/09/2018
(Oslo, Norway, September 5, 2018) Solon Eiendom ASA Board Member Tore Aksel Voldberg has today through his wholly owned company Dukat AS bought 5.000 shares in Solon Eiendom ASA at a price of NOK 28.0933. Following this [...]
Shire plc: Rule 2.9 Announcement
06/09/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 6 September 2018 [...]
Verona Pharma Announces Publication of Key Paper on RPL554 in COPD in the European Respiratory Journal
06/09/2018
Publication demonstrates RPL554’s significant bronchodilation effect, in both large and small airways, alone and when combined with currently used bronchodilators in COPD patients LONDON, Sept. 06, 2018 (GLOBE NEWSWIRE [...]
Nicox annonce son intention de réaliser une offre sous prospectus d'American Depository Shares au NASDAQ aux Etats-Unis
06/09/2018
Communiqué de presse Nicox annonce son intention de réaliser une offre sous prospectus d'American Depository Shares au NASDAQ aux Etats-Unis ................................................. 6 septembre 2018 - diffusion [...]
FIT Biotech Oy: FIT BIOTECH OY HALF-YEARLY FINANCIAL REPORT JANUARY 1 - JUNE 30, 2018
06/09/2018
FIT Biotech Oy Company release 6.9.2018 at 8:30 EET FIT BIOTECH OY HALF-YEARLY FINANCIAL REPORT JANUARY 1 - JUNE 30, 2018 Unaudited This company release is a summary of FIT Biotech's Half-yearly Financial Report January [...]
Nicox First Half 2018 Financial Results and Business Update
06/09/2018
Press Release Nicox First Half 2018 Financial Results and Business Update ................................................. NCX 470 Phase 2 clinical study initiated in Q3 2018 NCX 4251 on track for U.S. IND filing in Q1 [...]
Nicox : Résultats financiers du premier semestre 2018 et point des activités
06/09/2018
Communiqué de presse Nicox : Résultats financiers du premier semestre 2018 et point des activités ................................................. NCX 470 : Initiation d'une étude clinique de phase 2 au troisième [...]

Pages